Healthtech Solutions (OTC: HLTT), parent company of Medi-Scan Inc., today announced the incorporation of a new subsidiary called RevHeart Inc. According to the update, the new subsidiary will conduct further research into finding a treatment for COVID-related heart muscle injury. In direct support of the company’s ongoing efforts, RevHeart’s research team is developing the ability to identify and track myocardial deformities to enable implementation of a therapy to ameliorate and potentially repair myocardial damage. Based on positive results to date, RevHeart has filed a provisional patent application with the U.S. Patent and Trademark Office titled, “System, Method and Apparatus for Stimulating Cardiac Muscle Injury Recovery.” RevHeart will continue this research and development program with a goal of developing a combination therapy as a method of treatment for the detected myocardial injury. This includes a combination of stem cell therapy and electromagnetic field therapy, known as “entrainment.” Entrainment works to link the patient’s abnormal heart rhythm with a normal heart rhythm and gently encouraging the damaged heart to revert to a more normal rhythm.
To view the full press release, visit https://ibn.fm/UQP80
Healthtech Solutions Inc.
Healthtech Solutions, through its subsidiary, Mediscan Inc., offers technology that can transform 2D images from a portable ultrasound machine into digital 3D images to provide better diagnosis and more accurate internal trauma views. The technology has multiple applications in lung, cardiac and musculoskeletal imaging and related uses. For more information, visit the company’s website at www.MyMediScan.com.
NOTE TO INVESTORS: The latest news and updates relating to HLTT are available in the company’s newsroom at https://ibn.fm/HLTT
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.
With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.
Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
Editor@InvestorWire.com
InvestorWire is part of the InvestorBrandNetwork.